Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1–Infected Patients: A Multicenter Cohort Study in China: Erratum : JAIDS Journal of Acquired Immune Deficiency Syndromes

Secondary Logo

Journal Logo

Erratum

Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1–Infected Patients: A Multicenter Cohort Study in China: Erratum

JAIDS Journal of Acquired Immune Deficiency Syndromes 91(5):p 516, December 15, 2022. | DOI: 10.1097/QAI.0000000000003104
  • Free

For the article that published in the October 1, 2022 supplement issue of the journal (JAIDS 2022;91(S1):S42-S50), the authors wish to update the correspondence address as follows.

The correspondence line in the published article appeared as:

Hongxia Wei, Department of Infectious Disease, Nanjing Medical University, The Second Hospital of Nanjing, Zhongfu Road, Nanjing 210003, China (e-mail: [email protected]).

It should instead be:

Hongxia Wei, Nanjing Medical University; Department of Infectious Disease, The Second Hospital of Nanjing, Zhongfu Road, Nanjing 210003, China (e-mail: [email protected])

The authors apologize for this error.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.